Tetridar is indicated in adults for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. Teva says that in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures, but not hip fractures, have been demonstrated. Tetridar is also indicated in adults for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture. Further information is available upon request or from the SmPC available at hpra.ie.